Stathmin protein level has been shown to be a prognostic marker of aggressive disease in many cancers, including endometrial cancer, where high stathmin level in primary tumor identifies patients at high risk for recurrent disease and lymph node metastases [6], [9], [10], [12], [13], [15], [16]. This evidence concerns the gene STMN1 and cancer.